Furthermore, these findings suggest the potential for neutrophil‐targeted interventions, such as DNase or CXCR4 antagonists like AMD3100, to reduce thrombus formation and improve clinical outcomes specifically in CE stroke. This evidence concerns the gene CXCR4 and Stroke.